 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...8990919293949596979899...100101» |
- ||| letrozole / Generic mfg., everolimus / Generic mfg.
Trial initiation date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Apr 23, 2015
P2, N=202, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jul 2012 --> Mar 2013
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Clinical: Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov) - Apr 23, 2015
P3, N=5000, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jul 2012 --> Mar 2013 N=4000 --> 5000
- || letrozole / Generic mfg.
Trial primary completion date: Study of Breast Cancer Prevention by Letrozole in High Risk Women (clinicaltrials.gov) - Apr 22, 2015
P2, N=108, Active, not recruiting, Sponsor: Carol Fabian, MD
N=4000 --> 5000 Trial primary completion date: Jul 2014 --> Jul 2015
- ||||||| letrozole / Generic mfg., anastrozole / Generic mfg.
Trial completion: Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer (clinicaltrials.gov) - Apr 22, 2015
P3, N=4173, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2014 --> Jul 2015 Terminated --> Completed
- letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial primary completion date: Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Terminated --> Completed Trial primary completion date: Jan 2015 --> Jan 2014
- letrozole / Generic mfg.
Trial primary completion date, IO biomarker: Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. (clinicaltrials.gov) - Apr 18, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Trial primary completion date: Jan 2015 --> Jan 2014 Trial primary completion date: Feb 2015 --> Jun 2015
- MK-0752 / Merck (MSD)
Trial primary completion date, Combination therapy, Surgery: Study Of MK-0752 In Combination With Tamoxifen Or Letrozole to Treat Early Stage Breast Cancer (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=22, Active, not recruiting, Sponsor: Loyola University
Trial primary completion date: Feb 2015 --> Jun 2015 Trial primary completion date: Aug 2011 --> May 2015
- || letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial primary completion date: Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=150, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Aug 2011 --> May 2015 Trial primary completion date: Sep 2014 --> Sep 2015
- | letrozole / Generic mfg.
Enrollment change: Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS) (clinicaltrials.gov) - Apr 14, 2015
P3, N=140, Recruiting, Sponsor: Cairo University
Trial primary completion date: Sep 2014 --> Sep 2015 N=210 --> 140
- | Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
New P2 trial: PER-ELISA: Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy (clinicaltrials.gov) - Apr 9, 2015
P2, N=68, Recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
- |||||| Ibrance (palbociclib) / Pfizer
Enrollment open, Metastases: A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4] (clinicaltrials.gov) - Apr 7, 2015
P3, N=330, Recruiting, Sponsor: Pfizer
N=210 --> 140 Not yet recruiting --> Recruiting
- letrozole / Generic mfg.
Trial completion, Phase classification, Trial primary completion date, IO biomarker: Letrozole as a Treatment of Endometrial Cancer (clinicaltrials.gov) - Apr 6, 2015
P=N/A, N=43, Completed, Sponsor: University of California, Davis
Not yet recruiting --> Recruiting Recruiting --> Completed | Phase classification: P3 --> PN/A | Trial primary completion date: Aug 2012 --> Sep 2013
- || letrozole / Generic mfg.
New P2/3 trial, New P2a trial, New P3 trial: Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion (clinicaltrials.gov) - Apr 1, 2015
P2/3, N=400, Recruiting, Sponsor: Ain Shams University
- Kisqali (ribociclib) / Novartis, buparlisib (AN2025) / Adlai Nortye
Enrollment closed, Enrollment change, Combination therapy, Metastases: LeeBLet: Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (clinicaltrials.gov) - Apr 1, 2015
P1, N=13, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Phase classification: P3 --> PN/A | Trial primary completion date: Aug 2012 --> Sep 2013 Recruiting --> Active, not recruiting | N=50 --> 13
- tamoxifen / Generic mfg.
Biomarker, Enrollment closed, Monotherapy: PHACS: Pharmacology of Adjuvant Hormonotherapy in Breast Cancer (clinicaltrials.gov) - Mar 31, 2015
P4, N=2000, Active, not recruiting, Sponsor: Institut Claudius Regaud
Recruiting --> Active, not recruiting | N=50 --> 13 Recruiting --> Active, not recruiting
- Cetrotide (cetrorelix) / EMD Serono, Lutrelef (gonadorelin acetate) / Ferring
Trial completion: Reproductive Hormonal Alterations in Obesity (clinicaltrials.gov) - Mar 28, 2015
P=N/A, N=62, Completed, Sponsor: University of Colorado, Denver
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || letrozole / Generic mfg.
New P2/3 trial: Use of Letrozole Pretreatment With Misoprostol for First-Trimester Medical Abortion (clinicaltrials.gov) - Mar 27, 2015
P2/3, N=320, Recruiting, Sponsor: Ain Shams University
- ||| Ibrance (palbociclib) / Pfizer
Enrollment change, Metastases: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Mar 20, 2015
P1/2, N=177, Active, not recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed N=228 --> 177
- |||| cixutumumab (IMC A12) / Eli Lilly
Trial completion, Combination therapy, Metastases: A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer (clinicaltrials.gov) - Mar 20, 2015
P2, N=93, Completed, Sponsor: Eli Lilly and Company
N=228 --> 177 Active, not recruiting --> Completed
- |||| Kisqali (ribociclib) / Novartis
Enrollment open, Metastases: MONALEESASIA: A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer (clinicaltrials.gov) - Mar 17, 2015
P2, N=112, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Ibrance (palbociclib) / Pfizer
Enrollment open: PALLET: A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer (clinicaltrials.gov) - Mar 17, 2015
P2, N=306, Recruiting, Sponsor: NSABP Foundation Inc
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || letrozole / Generic mfg., tamoxifen / Generic mfg.
Enrollment closed: Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=610, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- letrozole / Generic mfg.
Enrollment closed: Outcome of Three Controlled Ovarian Hyperstimulation Protocols in Poor Responding Infertility Patients (clinicaltrials.gov) - Mar 9, 2015
P=N/A, N=95, Active, not recruiting, Sponsor: Istanbul University
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- letrozole / Generic mfg., menotropin / Generic mfg.
Enrollment closed: Comparison of Treatment Modalities in Poor Responders Undergoing IVF (clinicaltrials.gov) - Mar 9, 2015
P=N/A, N=80, Active, not recruiting, Sponsor: Ercan Bastu
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- letrozole / Generic mfg.
Clinical: Endocrinology Profile in Patients Undergoing Clomiphene, Letrozole, and Combination Clomiphene and Letrozole Cycles (clinicaltrials.gov) - Mar 3, 2015
P=N/A, N=10, Not yet recruiting, Sponsor: University Hospital Case Medical Center
- ||| letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Trial initiation date, Trial primary completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Mar 3, 2015
P2, N=202, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Initiation date: Mar 2013 --> Jul 2012 | Trial primary completion date: Jun 2016 --> Dec 2016
- letrozole / Generic mfg., clomifene citrate / Generic mfg.
Trial completion, Enrollment change: Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS (clinicaltrials.gov) - Mar 2, 2015
P0, N=100, Completed, Sponsor: Cairo University
Recruiting --> Active, not recruiting | Initiation date: Mar 2013 --> Jul 2012 | Trial primary completion date: Jun 2016 --> Dec 2016 Not yet recruiting --> Completed | N=80 --> 100
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Feb 27, 2015
P1, N=102, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Completed | N=80 --> 100 Trial primary completion date: Apr 2016 --> Nov 2016
- || Verzenio (abemaciclib) / Eli Lilly
Enrollment change: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Feb 23, 2015
P1, N=102, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Apr 2016 --> Nov 2016 N=81 --> 102
- ||| letrozole / Generic mfg., tamoxifen / Generic mfg., everolimus / Generic mfg.
Trial initiation date, Metastases: Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer (clinicaltrials.gov) - Feb 19, 2015
P2, N=72, Not yet recruiting, Sponsor: Gynecologic Oncology Group
N=81 --> 102 Initiation date: Oct 2014 --> Feb 2015
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Enrollment change: Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome. (clinicaltrials.gov) - Feb 19, 2015
P3, N=140, Recruiting, Sponsor: Cairo University
Initiation date: Oct 2014 --> Feb 2015 N=210 --> 140
- | letrozole / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer (clinicaltrials.gov) - Feb 19, 2015
P3, N=123, Terminated, Sponsor: Danish Breast Cancer Cooperative Group
N=210 --> 140 N=1500 --> 123 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Dec 2013; Poor recruitement
- letrozole / Generic mfg., clomifene citrate / Generic mfg.
Enrollment open: Ovulation Induction in Clomiphene Citrate Resistant PCO Women (clinicaltrials.gov) - Feb 18, 2015
P0, N=100, Recruiting, Sponsor: Cairo University
N=1500 --> 123 | Recruiting --> Terminated | Trial primary completion date: Jun 2024 --> Dec 2013; Poor recruitement Not yet recruiting --> Recruiting
- ||| letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Enrollment closed: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Feb 12, 2015
P2, N=84, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment open, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Feb 11, 2015
P2, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- Kisqali (ribociclib) / Novartis, buparlisib (AN2025) / Adlai Nortye
Trial primary completion date, Combination therapy, Metastases: LeeBLet: Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (clinicaltrials.gov) - Feb 2, 2015
P1, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Trial primary completion date: Aug 2016 --> Nov 2016
- letrozole / Generic mfg., clomifene citrate / Generic mfg.
Enrollment open: COOL-COS: COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (clinicaltrials.gov) - Feb 2, 2015
P4, N=40, Enrolling by invitation, Sponsor: University of Sao Paulo
Trial primary completion date: Aug 2016 --> Nov 2016 Not yet recruiting --> Enrolling by invitation
- letrozole / Generic mfg.
Enrollment closed, IO biomarker: Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. (clinicaltrials.gov) - Jan 30, 2015
P=N/A, N=30, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
Not yet recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- |||| metformin / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment open, Metastases: A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Jan 28, 2015
P2, N=64, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- || letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jan 26, 2015
P2, N=199, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Recruiting Trial primary completion date: Oct 2016 --> Jun 2016
- Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, pictilisib (GDC-0941) / Roche
Trial primary completion date: A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 26, 2015
P1, N=69, Active, not recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Oct 2016 --> Jun 2016 Trial primary completion date: Aug 2015 --> Jan 2016
- || Herceptin (trastuzumab) / Roche, Kisqali (ribociclib) / Novartis, Perjeta (pertuzumab) / Roche
New P3 trial: Detect V / CHEVENDO (Chemo vs. Endo) (clinicaltrials.gov) - Jan 26, 2015
P3, N=270, Not yet recruiting, Sponsor: Prof. W. Janni
- | New P2 trial, Metastases: LEO: Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer (clinicaltrials.gov) - Jan 26, 2015
P2, N=137, Recruiting, Sponsor: Asan Medical Center
- ||| lapatinib / Generic mfg., letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer (clinicaltrials.gov) - Jan 26, 2015
P2, N=76, Active, not recruiting, Sponsor: University of Maryland
Trial primary completion date: Aug 2015 --> Jan 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2014
- | Enrollment closed, Enrollment change, Surgery: Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery (clinicaltrials.gov) - Jan 22, 2015
P3, N=3600, Active, not recruiting, Sponsor: Gruppo Italiano Mammella (GIM)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2014 Recruiting --> Active, not recruiting | N=10000 --> 3600
- progesterone / Generic mfg., letrozole / Generic mfg., clomifene citrate / Generic mfg.
Clinical: Ovulation Induction in Clomiphene Citrate Resistant PCO Women (clinicaltrials.gov) - Jan 20, 2015
P0, N=100, Not yet recruiting, Sponsor: Cairo University
- || letrozole / Generic mfg., anastrozole / Generic mfg.
New P3 trial: POETIC: Trial of Perioperative Endocrine Therapy - Individualising Care (clinicaltrials.gov) - Jan 15, 2015
P3, N=4486, Active, not recruiting, Sponsor: Institute of Cancer Research, United Kingdom
- ||| letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Bolero-4: Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jan 15, 2015
P2, N=197, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=10000 --> 3600 Recruiting --> Active, not recruiting
- | Kisqali (ribociclib) / Novartis
Trial completion, Enrollment change, Trial primary completion date: A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) (clinicaltrials.gov) - Jan 13, 2015
P2, N=14, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Completed | N=120 --> 14 | Trial primary completion date: Feb 2015 --> Sep 2014
- | Ibrance (palbociclib) / Pfizer
Phase classification, Metastases: Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Jan 12, 2015
P1/2, N=228, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Completed | N=120 --> 14 | Trial primary completion date: Feb 2015 --> Sep 2014 Phase classification: P2 --> P1/2